Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles.
Journal: Cancer biology & therapy
Published: January 26, 2025
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer.
Journal: Endocrine-related cancer
Published: June 26, 2024
ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer.
Journal: Nucleic acids research
Published: February 02, 2024
Reproducible preclinical models of androgen receptor driven human prostate cancer bone metastasis.
Journal: The Prostate
Published: January 30, 2024
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
Journal: bioRxiv : the preprint server for biology
Published: October 31, 2023
Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full?
Journal: European urology
Published: January 10, 2023
Bipolar androgen therapy plus olaparib in men with metastatic castration-resistant prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: October 03, 2022
Sigma1 Regulates Lipid Droplet-mediated Redox Homeostasis Required for Prostate Cancer Proliferation.
Journal: Cancer research communications
Published: September 21, 2022
A Phase 1/2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Muscle-Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: September 12, 2022
Supraphysiological Androgens Promote the Tumor Suppressive Activity of the Androgen Receptor through cMYC Repression and Recruitment of the DREAM Complex.
Journal: Cancer research
Published: August 17, 2022
Statins and adrenal androgen levels in prostate cancer: A new twist.
Journal: EBioMedicine
Published: July 01, 2021
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Journal: The Journal of clinical investigation
Published: June 15, 2021
Last Updated: 09/26/2026